🔍

BAFNAPH - Bafna Pharma.

📊 NSE: BAFNAPH 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 18:52

📢 Recent Corporate Announcements

Bafna Pharma Q3 FY26 Net Profit Rises 94% YoY to ₹1.84 Cr; Revenue Up 15%

🔵 WATCH ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 05:50 PM

Bafna Pharmaceuticals reported a steady year-on-year performance for Q3 FY26, with revenue from operations growing 15.4% to ₹38.29 crore. Net profit nearly doubled YoY to ₹1.84 crore, although it saw a sequential decline from ₹3.12 crore in Q2 FY26. The company is currently navigating significant regulatory hurdles, including GST demands totaling approximately ₹5.66 crore and overdue foreign currency receivables of ₹2.05 crore. Despite these challenges, the nine-month profit before tax has improved significantly to ₹5.31 crore from ₹2.84 crore in the previous year.

Revenue from operations grew 15.4% YoY to ₹38.29 crore in Q3 FY26.
Net Profit for the quarter stood at ₹1.84 crore, up 93.8% from ₹0.95 crore in Q3 FY25.
Nine-month Profit Before Tax (PBT) surged to ₹5.31 crore compared to ₹2.84 crore in the prior year period.
Contingent liabilities include GST demands of ₹235.47 lakhs and ₹331.09 lakhs currently under appeal.
Foreign currency receivables of ₹2.05 crore are outstanding beyond RBI-stipulated timelines, requiring extension approvals.

💡 Investors should monitor the outcome of the GST appeals as the total demand of over ₹5.6 crore is substantial compared to annual profits. While operational growth is positive, the sequential margin compression and regulatory 'Emphasis of Matter' by auditors warrant a cautious approach.

Bafna Pharma Credit Outlook Upgraded to Positive by ICRA; Reaffirms BB+ Rating

🟢 POSITIVE ⭐ 6/10

ROUTINE 📅 23 Jan 2026, 07:07 PM

ICRA Limited has revised the credit outlook for Bafna Pharmaceuticals Limited from 'Stable' to 'Positive' while reaffirming its long-term rating at [ICRA] BB+. The rating applies to bank loan facilities totaling ₹50.00 crores, which include term loans of ₹25.87 crores and cash credit of ₹20.00 crores. Additionally, the short-term rating for non-fund-based facilities has been reaffirmed at [ICRA] A4+. This positive outlook indicates an expectation of improved financial stability and debt-servicing capability in the future.

Outlook revised from 'Stable' to 'Positive' for ₹50.00 crore total bank facilities.
Long-term rating reaffirmed at [ICRA] BB+ for ₹25.87 crore term loans and ₹20.00 crore cash credit.
Short-term rating for Letter of Credit facilities reaffirmed at [ICRA] A4+.
The revision reflects ICRA's assessment of an improving credit profile for the pharmaceutical firm.

💡 The outlook upgrade is a positive signal regarding the company's creditworthiness and could lead to lower interest expenses. Investors should monitor if this leads to a formal rating upgrade in the next 12 months.

Bafna Pharmaceuticals Submits SEBI Compliance Certificate for Quarter Ended Dec 31, 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 03:27 PM

Bafna Pharmaceuticals has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Cameo Corporate Services Limited, confirms that all dematerialization requests received during the quarter ended December 31, 2025, were processed within the stipulated time. It further verifies that physical share certificates were cancelled and the names of depositories were updated in the register of members. This is a standard procedural filing required for all listed companies in India to ensure the integrity of shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Registrar and Share Transfer Agent (RTA) Cameo Corporate Services confirmed all demat requests were handled as per regulations.
Physical share certificates were mutilated and cancelled after due verification by the depository participant.
The company confirmed that the securities are listed on the stock exchanges where earlier securities were listed.

💡 No action is required from investors as this is a routine regulatory compliance filing. Investors should focus on the company's upcoming financial results for material performance indicators.

Bafna Pharmaceuticals Closes Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Dec 2025, 12:42 PM

Bafna Pharmaceuticals Limited has announced the closure of its trading window starting January 01, 2026, in compliance with SEBI Insider Trading regulations. The closure pertains to the upcoming declaration of unaudited financial results for the quarter ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are made public. This is a standard regulatory procedure for listed companies in India to prevent insider trading before earnings announcements.

Trading window closure effective from January 01, 2026.
Closure relates to the financial results for the quarter ending December 31, 2025.
Window to reopen 48 hours after the official announcement of Q3 results.
Restriction applies to all Designated Persons and their immediate relatives as per SEBI norms.

💡 No action is required as this is a routine regulatory filing. Investors should await the announcement of the Q3 financial results to assess the company's operational performance.

View All BAFNAPH Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment: pharmaceutical formulations. Total revenue for FY 2024-25 was INR 145.86 Cr. For the half-year ended September 30, 2025, revenue was INR 70.09 Cr, representing a 4.78% decline compared to INR 73.61 Cr in the same period of the previous year.

Geographic Revenue Split

Approximately 50% of revenues are derived from exports. Key markets include regulated regions like the UK and Australia, and semi-regulated/unregulated markets such as the Philippines, Sri Lanka, Ethiopia, Ukraine, Nigeria, and Tanzania.

Profitability Margins

Operating Profit Margin improved to 6.19% in FY 2024-25 from 4.82% in FY 2023-24 (a 28.42% improvement) due to expense reduction. However, Net Profit Margin fell to 2.72% from 4.82% (a 43.57% decline) primarily due to a significant asset write-off and increased borrowing costs.

EBITDA Margin

EBITDA Margin stood at 9.54% for FY 2024-25, showing a marginal decline of 0.63% from 9.60% in FY 2023-24, indicating stable core operational profitability despite bottom-line pressures.

Capital Expenditure

The company has a total planned capex of INR 24.5 Cr over three years: INR 11.5 Cr in FY 2025, INR 10.0 Cr in FY 2026, and INR 3.0 Cr in FY 2027, focused on capacity expansion and maintenance.

Credit Rating & Borrowing

ICRA reaffirmed ratings at [ICRA]BB+ (Stable) for long-term and [ICRA]A4+ for short-term facilities as of April 2025. CRISIL previously withdrew its 'D' rating in 2020 following a 'no dues certificate' from bankers.

⚙️ Operational Drivers

Capacity Expansion

Planned expansion involves a capex of INR 11.5 Cr in FY 2025 and INR 10.0 Cr in FY 2026 to increase manufacturing scale and support growth in lifestyle disease segments.

Manufacturing Efficiency

The company focuses on the lifestyle diseases segment (diabetology, CNS, respiratory) to optimize its manufacturing mix for higher-demand therapeutic areas.

📈 Strategic Growth

Growth Strategy

Growth is targeted through a three-year INR 24.5 Cr capex plan for capacity expansion, focusing on the lifestyle disease segment (diabetology, pain management), and leveraging established relationships with major players like Cipla and Strides Pharma.

Products & Services

Pharmaceutical formulations including Metformin (diabetology), Fluoxetine (CNS), and Quilonum (CNS).

Brand Portfolio

Metformin, Fluoxetine, and Quilonum.

New Products/Services

The company is focusing on emerging opportunities in CRAMS (Contract Research and Manufacturing Services) and biosimilars to diversify its revenue streams.

Market Expansion

Targeting expansion in regulated markets like the UK and Australia, alongside emerging markets in Africa and the Commonwealth countries.

Strategic Alliances

Maintains established contract manufacturing relationships with Cipla Limited and Strides Pharma Science Limited.

🌍 External Factors

Industry Trends

The Indian pharma industry is shifting toward CRAMS, biosimilars, and digital health. Long-term competitiveness depends on innovation and strategic global partnerships to navigate supply chain and margin pressures.

Competitive Landscape

Competes with other Indian formulation manufacturers in both regulated and semi-regulated markets; market dynamics are driven by pricing and manufacturing compliance standards.

Competitive Moat

Moat is built on 3 decades of manufacturing experience and established relationships with global pharma leaders, though it is challenged by high customer concentration and regulatory compliance requirements.

Macro Economic Sensitivity

Sensitive to global healthcare spending and regulatory changes in export markets like the UK and Australia.

Consumer Behavior

Increasing prevalence of lifestyle diseases (diabetes, respiratory issues) is driving sustained demand for the company's core product portfolio.

Geopolitical Risks

Operations in Ukraine and various African nations expose the company to regional geopolitical instability and trade barrier risks.

⚖️ Regulatory & Governance

Industry Regulations

Subject to high manufacturing compliance standards and government price controls/caps, which are identified as key social and regulatory risks.

Taxation Policy Impact

The company is involved in pending litigations concerning direct and indirect tax matters with various statutory authorities.

Legal Contingencies

Pending litigations include direct and indirect tax disputes. Additionally, the company faced non-compliance issues with SEBI regarding Minimum Public Shareholding and appointment of a Compliance Officer, for which penalty provisions have been made.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the 'temporary' derecognition of INR 1.77 Cr in intangible assets and the potential for future write-downs if product registrations do not yield economic benefits.

Geographic Concentration Risk

While diversified, the company relies heavily on the UK and Australia for regulated market revenue, making it sensitive to regulatory shifts in those two regions.